Disassembly of the JIP1/JNK molecular scaffold by caspase-3-mediated cleavage of JIP1 during apoptosis  by Vaishnav, Mahesh et al.
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 7 ( 2 0 1 1 ) 1 0 2 8 – 1 0 3 9
ava i l ab l e a t www.sc i enced i r ec t . com
www.e l sev i e r . com/ loca te /yexc rResearch Article
Disassembly of the JIP1/JNK molecular scaffold by
caspase-3-mediated cleavage of JIP1 during apoptosisMahesh Vaishnava,1, Marion MacFarlaneb, Martin Dickensa,⁎
aDepartment of Biochemistry, Henry Wellcome Building, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK
bMedical Research Council Toxicology Unit, Hodgkin Building, University of Leicester, P.O. Box 138, Lancaster Road, Leicester LE1 9HN, UKA R T I C L E I N F O R M A T I O N⁎ Corresponding author. Fax: +44 116 229 701
E-mail address: md38@le.ac.uk (M. Dickens
Abbreviations: DEVD.fmk, benzyloxycarbony
diamine tetra-acetic acid; FADD, Fas-associate
protein; JIP, JNK interacting protein; JNK, c-jun a
MAPKK kinase; NF-κB, Nuclear factor κB; PARP,
kinase; POSH, Plenty of SH3s; TNF, tumour necr
TRAIL, TNF-related apoptosis inducing ligand; z
1 Present address: Department of Cell Biology
0014-4827 © 2011 Elsevier Inc.
doi:10.1016/j.yexcr.2011.01.011
Open access under A B S T R A C TArticle Chronology:
Received 18 September 2010
Revised version received
5 January 2011
Accepted 5 January 2011
Available online 13 January 2011We report here the cleavage of the c-Jun N-terminal Kinase (JNK) pathway scaffold protein, JNK
Interacting Protein-1 (JIP1), by caspases during both Tumour Necrosis Factor-Related Apoptosis-
Inducing Ligand (TRAIL) and staurosporine-induced apoptosis in HeLa cells. During the initiation
of apoptosis, maximal JNK activation is observed when JIP1 is intact, whereas cleavage of JIP1
correlates with JNK inactivation and progression of apoptosis. JIP1 is cleaved by caspase-3 at two
sites, leading to disassembly of the JIP1/JNK complex. Inhibition of JIP1 cleavage by the caspase-3
inhibitor DEVD.fmk inhibits this disassembly, and is accompanied by sustained JNK activation.
These data suggest that TRAIL and staurosporine induce JNK activation in a caspase-3-independent
manner and that caspase-3-mediated JIP1 cleavage plays a role in JNK inactivation via scaffold
disassembly during the execution phase of apoptosis. Caspase-mediated cleavage of JIP scaffold
proteinsmay therefore represent an important mechanism formodulation of JNK signalling during
apoptotic cell death.







Apoptosis is a conserved, intrinsic cellular suicide programme that
is fundamental for the normal development and homeostasis of
multicellular organisms [reviewed in [1,2]]. It is characterised by a
distinct set of morphological and biochemical changes that
ultimately result in the controlled dismantling and removal of8.
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requires the close integration of cell signalling pathways with
the core apoptotic machinery.
Mammalian caspases are divided into ‘initiator’ and ‘effector’
caspases. Initiator caspases (e.g. caspases-8 and -9) directly or
indirectly activate effector caspases (e.g. caspases-3, -6 and -7).
These effector caspases then cleave key intracellular substrates such
as Poly (ADP-ribose) Polymerase (PARP) and lamins, resulting in the
classical morphological features of apoptosis [3].
Caspases may be activated by both receptor (‘extrinsic’)- and
non-receptor (‘intrinsic’)-mediated apoptotic pathways [reviewed
in [2,4]]. The extrinsic pathway is activated by transmembrane
proteins that belong to the tumour necrosis factor (TNF)/nerve
growth factor (NGF) receptor superfamily. These include, the death
receptors Fas (CD95/Apo1), TNFR-I and the two TNF-related
apoptosis-inducing ligand (TRAIL) receptors, TRAIL-R1 and TRAIL-
R2 [reviewed in [5]]. Fas, TNFR and TRAIL receptor ligation results in
receptor trimerisation and binding of death domain-containing
adaptor proteins such as FADD, TRADD, and TRAF2. FADD in turn
recruits the apical caspase pro-caspase-8, thereby inducing forma-
tion of the Death-Inducing Signalling Complex (DISC) and auto-
catalytic activation of caspase-8.
The intrinsic apoptotic pathway is activated by a wide variety of
toxic chemicals (e.g. staurosporine) and other stress-inducing
stimuli [reviewed in [6]]. This pathway is characterised by the
release of cytochrome c from mitochondria, which together with
Apaf-1 and dATP results in formation of the ‘apoptosome’ and
subsequent activation of pro-caspase-9. Caspase-9, in turn, activates
effector caspases including caspases-3 and -7 and is therefore the
primary initiator caspase for the intrinsic apoptotic pathway
[reviewed in [4,7]].
The c-JunN-terminal Kinase or JNK family of protein kinases are a
group of enzymes that are activated by the exposure of cells to
cytokines and a wide variety of environmental stresses. The
proposed immediate upstream regulators of JNK are theMAPKinase
Kinases (MKKs) MKK4 and MKK7, which phosphorylate T183 and
Y185 in the activation loop of JNK. Numerous MAP Kinase Kinase
Kinases (MKKKs) that activateMKKs have been proposed [reviewed
in [8–10]].
The role of JNK in apoptosis is complex and context-dependent.
JNK activation is observed during apoptosis induced by a wide
variety of stimuli in many cell types [10–14]. Studies using JNK
deficient cells suggest that JNK activation is required for the proper
regulation of stress-induced apoptosis. JNK activates the pro-
apoptotic Bcl-2 family members Bax, Bid and Bim causing the
releaseof cytochromec andSmac/Diablo frommitochondria, leading
to the activation of caspases via the “apoptosome” [10,15–22].
However, there is also good evidence to suggest that the JNK
pathway may also contribute to cell survival in some circumstances
[23–30].
A family of scaffold proteins, called JNK-Interacting Proteins
(JIPs), has been identified [31–34]. These include JIP1 and JIP2 [also
known as IB1/2 [35,36]] and JIP3/JSAP [33,37]. These proteins are
thought to organise the components of the JNK pathway into specific
signalling complexes [38]. Thus the JIP proteins are able to bind
MLK3, MKK7 and JNK in a manner which may facilitate JNK
signalling and activation [32,33,39,40].
The more recently identified scaffold protein JIP4, and the
highly related JLP, appear to interact with both JNK and p38
[41,42]. Other scaffold proteins, such as POSH, may also beinvolved in the assembly of functional JNK/JIP-containing signal-
ling complexes [43,44].
Mathematical modelling of MAPK pathway regulation by
scaffold proteins shows that the level of MAPK activity is
dependent on the level of expression of scaffold proteins in the
cell [45,46]. Thus, the stoichiometry of the JIP signalling complexes
involved in JNK activation depends on the level of JIP expression,
and is likely to be important for determining JNK activity in the
cell. Modulation of JIP levels may therefore provide a mechanism
for the regulation of JNK activity and hence apoptosis in a context-
dependent manner [40,47–52].
In a previous study we have shown that JNK activation during
apoptosis induced by the proteasome inhibitor, lactacystin, is
potentiated in the presence of caspase inhibitors [12]. In addition,
inspection of the primary sequence of the JNK pathway scaffold
protein JIP1, revealed putative caspase cleavage sites within the
protein. These observations suggest that caspases may cleave the
JNK pathway scaffold protein JIP1 to allow modulation of JNK
activation during apoptosis.
We report here the cleavage of JIP1 by caspase-3 during receptor-
and chemically-induced apoptosis in HeLa cells. Cleavage of JIP1 leads
to disassembly of the JNK/JIP1 complex and correlates with JNK
inactivation and progression of apoptosis. Caspase-mediated cleavage
of JIP scaffold proteins may therefore represent an important
mechanism enabling cells to switch off signalling by the JNK pathway
once cells are committed to apoptosis.Materials and methods
Cell culture and treatments
HeLa cells were maintained in Dulbecco's Modified Eagle Medium
supplementedwith10%(v/v) foetal bovine serum,2 mML-Glutamine
and 100 units/ml each of penicillin and streptomycin. Cells were
grown in an atmosphere of 5% CO2 at 37 °C. Cells were plated onto
100 mmdishes, grown to 75% confluence and treatedwith TRAIL [53]
or staurosporine (Sigma, UK),with orwithout 1 h pre-treatmentwith
benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethyl ketone (zVAD.
fmk) (Enzyme Systems, Dublin, CA) or benzyloxycarbonyl-Asp
(OMe)-Glu(OMe)-Val-Asp(OMe) fluoromethyl ketone (DEVD.fmk)
(Alexis Biochemicals, Nottingham, UK) as described in the figure
legends. Non-adherent cells were collected by centrifugation at 100 g
at 4 °C for 3 min, washed once with ice-cold PBS and lysed in Triton
Lysis Buffer (20 mM Hepes pH 7.5, 137 mM NaCl, 25 mM β-glycerol
phosphate, 2 mM sodium pyrophosphate, 2 mM EDTA, 10% glycerol,
1%TritonX-100, 1 mMPMSF, 2.5 μg/mleachofpepstatin, antipainand
leupeptin, and 2 mM benzamidine, 0.5 mM DTT, 1 mM Na3VO4).
Attached cells were also washed once with ice-cold PBS and lysed in
Triton Lysis Buffer. Lysates from non-adherent and adherent
cells were pooled, clarified by centrifugation at 20, 000 g for 15 min
at 4 °C, and the protein concentration determined by the method of
Bradford [54].
Quantification of apoptosis
For quantitative apoptosis measurements, cells were plated onto
22×22 mm glass coverslips and treated with the apoptotic agents
for the times indicated in the figure legends. Non-adherent
apoptotic cells were collected from the medium by centrifugation
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cence microscopy alongside coverslips containing adherent cells.
Cells were fixed with ice-cold methanol for 30 min at−20 °C and
washed three times with calcium- andmagnesium-free PBS before
blocking in PBS/1% BSA at room temperature for 1 h. Cells were
then washed five times with calcium- and magnesium-free PBS,
and incubated with 1 μM Hoechst 33258 for 5 min at room
temperature. Finally, cells were then washed three times with
calcium- and magnesium-free PBS before mounting. The percen-
tage of apoptotic cells was determined, using fluorescence
microscopy, by counting the number of cells undergoing nuclear
fragmentation as described previously [13].
Western blot analysis
Cell lysates (200 μg) were subjected to SDS-PAGE and proteins
transferred to Immobilon-P membranes (Millipore) by electro-
phoresis using a semi-dry transfer apparatus (Biorad). Western
blots were probed with monoclonal antibodies to JIP1 (The kind
gift of Dr. Roger Davis, HHMI,Worcester, USA), PARP (Pharmingen,
cat. # 65196E), α-tubulin (Sigma, cat. # T5168), JNK1 (Pharmin-
gen, cat. # 554286), and caspase-3 (kindly provided by Dr D.
Nicholson, Merck Frosst), -7, -8 or -9 (kindly provided by Dr D.
Green, Memphis) as indicated in the figure legends. Blots were
further developed by incubation with appropriate HRP-conjugated
secondary antibodies (Sigma) and visualised using enhanced
chemiluminescence (GE Healthcare).
In vitro translation and caspase cleavage reactions
[35S] Methionine-labelled JIP1 proteins were prepared by coupled
in vitro transcription/translation of 2 μg of a pBluescript-JIP1 cDNA
template, in a TNT® rabbit reticulocyte lysate, according to the
manufacturer's instructions (Promega). For in vitro caspase
cleavage reactions, a 10 μl aliquot of the transcription/translation
mixture, containing [35S]-labelled JIP1, was incubated with
purified recombinant caspase-3 or -8, as indicated, in a final
volume of 25 μl containing 10 mMHepes, pH 7.5, 2 mM EDTA, 0.1%
CHAPS, 10 μg/ml antipain, 10 μg/ml pepstatin A, 20 μg/ml leupep-
tin, 2 mM PMSF, and 5 mMDTT [55]. The reactions were incubated
at 30 °C for the times indicated and were terminated by the
addition of SDS-PAGE sample buffer prior to SDS-PAGE on 10%
gels. Gels were stained with Coomassie Brilliant Blue G250,
destained, dried and the reaction products visualised by Phos-
phorImager analysis (GE Healthcare).
JIP1 mutagenesis
Caspase-3 cleavage-resistant JIP1 mutants, DLIA and DESA and the
double mutant DLIA/DESA were constructed by overlap extension
PCR-mutagenesis with mismatch oligonucleotide primers using
pBluescript-JIP1 as a template. All mutations were confirmed by
automated DNA sequencing (Applied Biosystems).
Immunoprecipitation and JNK Immune-complex
kinase assays
After the indicated treatments and extraction, clarified HeLa cell
lysates (400 μg) were pre-clearedwith 5 mg of protein-A Sepharose
(Sigma) for 1 h at 4 °C. Lysates were then incubated, for 3 h at 4 °C,with 5 mg Protein-A Sepharose and rabbit polyclonal antisera raised
against full length JNK1. Immunoprecipitates were then washed
three times with 1 ml of ice-cold Triton Lysis Buffer and either
subjected to SDS-PAGE prior to western blotting for JIP1 or assayed
for JNK activity. For JNK assays, the immunoprecipitateswere further
washed with 1 ml of Kinase Assay Buffer (25 mM Hepes pH 7.4,
25 mM β-glycerol phosphate, 25 mM MgCl2, 0.5 mM Na3VO4, and
0.5 mM DTT) and resuspended in Kinase Assay Buffer to a final
volume of 50 μl containing 50 μM [γ -32P] ATP (2000 cpm/pmol)
and 5 μg GST-c-Jun (1-79). After incubation for 30 min at 30 °C,
assays were terminated by the addition of SDS-PAGE sample buffer,
prior to electrophoresis on 10% SDS-PAGE gels. 32P-incorporation
into GST-c-Jun was determined by PhosphorImager analysis of the
dried gels (GE Healthcare).Results
Caspase-mediated cleavage of JIP1 occurs during TRAIL and
staurosporine-induced apoptosis of HeLa cells
The presence of putative caspase cleavage sites within the primary
sequence of JIP1 raised the possibility that JIP1 might be cleaved
during apoptosis to yield a protein product with potentially
modified properties.
To test whether JIP1 is cleaved in vivo by caspases, HeLa cells were
treated with either TRAIL (Fig. 1) or staurosporine (Fig. 2) in the
presenceor theabsenceof thegeneral caspase inhibitor zVAD.fmk. The
number of apoptotic cellswasmonitored and cell extracts subjected to
western blotting for JIP1, PARP and α-tubulin (Figs. 1A and 2A).
Both TRAIL and staurosporine induced a time-dependent
increase in the number of apoptotic cells in the culture that was
inhibited by the general caspase inhibitor zVAD.fmk (Figs. 1A and
2A). In untreated HeLa cells, both JIP1 and PARP were present as
intact polypeptides of 120 kDa and 116 kDa respectively. TRAIL
caused the time-dependent loss of the 120 kDa, intact, form of JIP1
and the appearance of a 100 kDa fragment, first evident at 4 h,
suggesting the proteolytic cleavage of JIP1 during apoptosis. Similar
results were obtained in response to staurosporine treatment,
although the kinetics were slower, with significant accumulation
of the 100 kDa species evident only after 8 h. JIP1 cleavage in
response to either stimulus was accompanied by a decrease in the
amount of intact JIP1. However, in both cases, neither the complete
loss of intact JIP1, nor the appearance of fragments smaller than
100 kDa was observed. Following exposure to both TRAIL and
staurosporine, production of the 100 kDa fragment was completely
blocked by the caspase inhibitor zVAD.fmk, indicating that cleavage
of JIP1 in vivo during apoptosis is mediated by a caspase.
Treatment of HeLa cells with TRAIL or staurosporine caused a
similar time-dependent cleavage of the caspase-3 substrate, PARP,
which was cleaved to an 85 kDa fragment after 2 h in response to
TRAIL (Fig. 1A), and after 1 h of staurosporine treatment (Fig. 2A).
Complete loss of intact PARP was observed after 4 h of TRAIL and
8 h of staurosporine treatment. As expected, PARP cleavage was
completely blocked by zVAD.fmk pre-treatment in response to
either stimulus. Constant levels of α-tubulin throughout the time
course, for both TRAIL and staurosporine treatment, confirmed
equal protein loading and excluded the possibility that JIP1
cleavage might have been due to non-specific proteolysis.
Fig. 1 – Caspase-mediated JIP1 cleavage during TRAIL induced
apoptosis of HeLa cells. HeLa cells were treated with TRAIL
(1 μg/ml) with or without 50 μM zVAD.fmk (added 1 h prior to
the addition of TRAIL) for the times indicated. Adherent and
non-adherent cells were collected, the percentage of apoptotic
cells determined, and cell lysates immunoblotted with either
monoclonal antibodies to JIP1, PARP and α-tubulin (A) or
polyclonal antibodies raised against caspases-3, -7, -8 and
-9 (B).
Fig. 2 – Caspase-mediated JIP1 cleavage during staurosporine
induced apoptosis of HeLa Cells. HeLa cells were treated with
staurosporine (1 μM) with or without 50 μM zVAD.fmk (added
1 h prior to the addition of staurosporine) for the times
indicated. Adherent and non-adherent cells were collected, the
percentage of apoptotic cells determined, and cell lysates
immunoblotted with either monoclonal antibodies to JIP1,
PARP and α-tubulin (A) or polyclonal antibodies raised against
caspases-3, -7, -8 and -9 (B).
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TRAIL and staurosporine suggesteddifferential activation of caspases
by these two stimuli. To test this, and to determine if the kinetics of
JIP1 cleavage correlatedwith activation of a specific caspase, extracts
of HeLa cells treated with TRAIL and staurosporine were examined
for caspase activation by western blotting with antisera reactive to
caspases -3, -7, -8 and -9 (Figs. 1B and 2B).
Caspases-3 and -7 were present primarily as their intact 32 kDa
and 36 kDa proforms in control cells (Figs. 1B and 2B). Treatmentwith TRAIL or staurosporine resulted in the gradual loss of the
inactive proforms and the concomitant appearance, first detected
at 2 h, of their active 17 kDa and 19 kDa forms respectively
(Fig. 1B). However, the kinetics of caspases-3 and -7 processing
was slower in response to staurosporine, with a modest amount of
their active fragments evident in cells treated with staurosporine
compared with those treated with TRAIL (Fig. 2B). Staurosporine
treatment for 4 h resulted in the efficient processing of caspases-3
and -7 and an increased formation of their active fragments that
Fig. 3 – Effect of caspase inhibitors on JIP1 cleavage during
TRAIL-induced apoptosis of HeLa cells. HeLa cells were treated
with TRAIL (1 μg/ml) for 8 h in the presence or absence of
either 50 μM zVAD.fmk or DEVD.fmk at the concentrations
indicated. Caspase inhibitors were added 1 h prior to the
addition of TRAIL. Adherent and non-adherent cells were
collected and the percentage of apoptotic cells determined and
lysates immunoblotted for JIP1 and PARP as indicated. Similar
results were obtained with staurosporine (not shown).
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(Figs. 1B and 2B).
Caspase-8 was present primarily as two isoforms of very
similar mobility, running at an apparent molecular weight of
55 kDa (Figs. 1B and 2B), corresponding to caspases-8a and -8b.
Exposure to TRAIL or staurosporine resulted in the cleavage of
caspase-8 initially to two fragments of 43 and 41 kDa. This was
followed by the appearance of the active 18 kDa fragment, first
observed 2 h after TRAIL treatment (Fig. 1B), but not evident until
8 h following exposure to staurosporine (Fig. 2B).
In untreated HeLa cells caspase-9 was evident as an inactive
46 kDa proform which, upon the induction of apoptosis, by either
TRAIL or staurosporine, was processed in a time-dependent
manner to yield the active 35 kDa fragment, which first appeared
at 2 h (Figs. 1B and 2B).
Processing of all caspases to their corresponding active forms,
in response to either stimulus, was significantly inhibited in cells
pre-treated with the broad spectrum caspase inhibitor zVAD.fmk
(Figs. 1B and 2B).
These results demonstrate that TRAIL and staurosporine show
different kinetics of activation of both the initiator caspases (-8 and -9)
and the effector caspases (-3 and -7). This was consistent with the
differential kinetics of JIP1 cleavage observed in response to TRAIL and
staurosporine in HeLa cells (Figs. 1A and 2A).
JIP1 is a caspase-3 substrate in vivo
The potential caspase cleavage sites identified by inspection of the
sequence of JIP1 most closely resembled the consensus sequence
proposed for the major effector caspase, caspase-3 [3]. In addition,
the kinetics of JIP1 cleavage in response to TRAIL and staurosporine
are consistent with JIP1 being a caspase-3/-7 substrate.
To investigate the possibility that JIP1 might be a caspase-3/-7
substrate in vivo, HeLa cells were pre-treated with increasing
concentrations of a more specific caspase-3/-7 inhibitor, DEVD.
fmk, and exposed to TRAIL for 8 h. Extracts were then prepared
and blotted for JIP1 and the caspase-3 substrate, PARP. In control
cells JIP1 and PARP were present as 120 kDa and 116 kDa
fragments respectively (Fig. 3). TRAIL treatment in the absence
of DEVD.fmk resulted in the cleavage of JIP1 to a ~100 kDa product,
and cleavage of PARP to an 85 kDa fragment. Increasing concen-
trations of DEVD.fmk resulted in the progressive inhibition of JIP1
cleavage, with complete inhibition seen at 40 μM (Fig. 3). In
addition, we confirmed that 40 μM DEVD.fmk inhibited caspase-3
activity completely but had no effect on caspase-8 processing or
activity (data not shown). Inhibition of JIP1 cleavage by DEVD.fmk
was comparable to the inhibition achieved with zVAD.fmk. A
concentration-dependent inhibition of PARP cleavage in the
presence of DEVD.fmk was also observed, with 40 μM DEVD.fmk
inhibiting PARP cleavage and thus demonstrating the complete
inhibition of caspase-3 activity. Identical results were obtained for
the inhibition of JIP1 cleavage by DEVD.fmk in staurosporine
treated HeLa cells (not shown). These results clearly demonstrate
that JIP1 is a caspase-3 substrate in vivo.
Preferential cleavage of JIP1 by caspase-3 in vitro
To confirm that JIP1 was a caspase-3 substrate, and to detect
additional JIP1 cleavage products not detected by our JIP1
antibody, we incubated 35S-labelled JIP1, prepared by in vitrotranscription/translation, with increasing concentrations of purified
recombinant caspase-3 in vitro (Fig. 4A). Purified recombinant
caspase-8 was used for comparison.
In the absence of purified recombinant caspases, JIP1waspresent
as an intact 120 kDapolypeptide.Minor bands,migrating at ~80 kDa
and ~50 kDa, marked as a and b respectively in Fig. 4A, were also
present. Upon incubation with 2.5 nM caspase-3, in addition to the
intact 120 kDa JIP1polypeptide, fragments of ~100, ~55and~45 kDa
were also detected (Fig. 4A). At very high concentrations of caspase-
3 a minor 37 kDa species was also detected. The 100 kDa JIP1
fragment detected in vitro is very likely to correspond to the 100 kDa
JIP1 species observed during apoptosis in vivo,which is detected by
immunoblotting. Increasing concentrations of caspase-3 resulted in
the loss of the 120 kDa and 100 kDa fragments and an increase in the
formation of the 55 kDa and 45 kDa products. The 100 kDa and
45 kDa products were not detected upon incubation with purified
recombinant caspase-8 at the equivalent concentration of 2.5 nM.
Products of this size were only just detectable even upon incubation
with caspase-8 at higher concentrations. An essentially identical set
of fragments were obtained in a time course of digestion at a fixed
caspase concentration of 10 nM (Fig. 4B). These results demonstrate
that JIP1 is an efficient caspase-3 substrate in vitro and is cleaved
preferentially by caspase-3 rather than caspase-8.
Cleavage of JIP1 by caspase-3 occurs in vitro at two sites
The formation of three major products (100 kDa, 55 kDa and
45 kDa) on incubation of JIP1 with caspase-3 suggests two major
cleavage sites. Inspection of the amino acid sequences for JIP1
indicate two conserved putative caspase-3 cleavage sites with
Fig. 4 – Cleavage of JIP1 by caspases-3 and -8 in vitro. 35S-labelled, in vitro translated JIP1 was incubated with either (A) varying
concentrations of purified caspase-3 or -8 for 1 h at 30 °C or (B) a fixed concentration of caspase-3 or -8 (10 nM) for the times
indicated. The reaction products were visualised by SDS-PAGE and autoradiography. The migration of two minor translation
products (a and b) are indicated. Band a is likely to have arisen due to the use of an alternative internal translational initiation site.
The identity of band b is unknown, but appears to be unrelated to JIP1 since its intensity is unaffected by caspase treatment.
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produced by caspase-3 digestion is entirely consistent with
cleavage occurring preferentially at these sites (Fig. 5B). To
confirm this directly we replaced the aspartic acid residues at
the cleavage site with alanine by site-directed mutagenesis
(DLID→DLIA, DESD→DESA and the double mutant DLIA/DESA)
and tested their efficiency as substrates for caspase-3 in vitro
(Fig. 5C).
Equivalent amounts of 35S-labelled, in vitro translated JIP1
(wild-type), JIP1 (DLIA), JIP1 (DESA) and JIP1 (DLIA/DESA) were
incubated in the presence or the absence of 10 nM purified
caspase-3, and the reaction products visualised by SDS-PAGE and
autoradiography. In the absence of purified caspase-3, the wild-
type and mutant JIP1 proteins were present as full length 120 kDa
polypeptides (Fig. 5B). Minor translation products were also
detected running at approximately 80 kDa and 50 kDa as seen
previously (Figs. 4A and B). As expected, wild-type JIP1 was
cleaved by caspase-3 to yield three major products of approxi-
mately ~100 kDa, ~55 kDa and ~45 kDa, with a considerable loss
of the intact protein (Fig. 5B). Incubation of the in vitro translated
JIP1(DLIA) with purified caspase-3 did not result in the formation
of the 100 kDa and 55 kDa products produced from the wild-type
JIP1. However, the 45 kDa product was still evident and there was
a significant increase in the production of a 75 kDa species.
Cleavage of the in vitro translated JIP1(DESA) with purified
caspase-3 led to a significant loss of the intact protein and the
formation of the 100 kDa product, but the 45 kDa and 50 kDa
products were not detected (Fig. 5B). Neither was the 75 kDa
product detected on cleavage of the DESA mutant by caspase-3.The JIP1 double mutant (DLIA/DESA) was entirely resistant to
cleavage by caspase-3. Taken together these data confirm that JIP1
is a caspase-3 substrate in vitro and that the preferred cleavage
sites are DLID and DESD, with no additional sites.
The caspase-3 inhibitor DEVD.fmk potentiates JNK activation
during TRAIL and staurosporine induced apoptosis
JNK activation precedes the induction of, and contributes to,
apoptosis in many cell types. Since JIP1 has been implicated as a
scaffold protein that organises and regulates the activity of the JNK
module [39] its cleavage by caspase-3 may have consequences for
the activity of the JNK pathway during apoptosis. To test the
hypothesis that JIP1 cleavage during apoptosis may lead to
changes in JNK activity we measured the JNK activity profile
during TRAIL and staurosporine-induced apoptosis of HeLa cells in
the presence and absence of the caspase-3 inhibitor, DEVD.fmk
(Figs. 6A and B).
HeLa cells were treated with TRAIL or staurosporine, in the
presence or absence of 40 μM DEVD.fmk, and cell extracts
prepared from adherent and non-adherent cells were assayed for
JNK activity (Fig. 6). Throughout the time course JNK activity
remained at basal level in control cells and also in cells treated
with DEVD.fmk alone (Figs. 6A and B). Consistent with our
previous observations [12] TRAIL caused an ~8-fold increase in
JNK activity at 2 h, followed by a steady decline to ~3-fold at 8 h
(Fig. 6A). In staurosporine-treated cells, JNK activity increased
more slowly, reaching a maximum of 6-fold above the basal level
after 4 h (Fig. 6B). However, on reaching this peak it declined
Fig. 5 – Identification of caspase-3 cleavage sites in JIP1. (A) Sequence alignment showing conserved caspase-3 cleavage sites in JIP1
from various species. (B) A diagram of JIP1 indicating the proposed sites of caspase-3 cleavage and the sizes of the expected cleavage
products. Also shown are the positions of the JNK binding domain (JBD), Src homology 3 domain (SH3) and phosphotyrosine binding
domain (PTB). (B)Wild-type and cleavage-resistant JIP1mutants DLIA, DESA and the doublemutant DLIA/DESAwere 35S-labelled by in
vitro translationand incubatedwithorwithout10 nMcaspase-3 for 1 hat 30 °C. The reactionproductswere visualisedbySDS-PAGEand
autoradiography.
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fold above the basal level (Fig. 6B). In both TRAIL and staurosporine
treated cells the decline in JNK activity after the initial peak, at either
2 or 4 h respectively,wasmarkedly attenuated in the presence of the
caspase-3 inhibitor DEVD.fmk. In cells incubated with TRAIL and
DEVD.fmk, JNK activity was significantly elevated at 4 h and 8 h
when compared to cells treated with TRAIL alone (p<0.05; Fig. 6A).
Although in staurosporine treated cells, no effect of DEVD.fmk was
evident at 4 h, at 8 h JNK activity in the presence of the inhibitorwas
significantly higher than in cells treated without DEVD.fmk
(p<0.05; Fig. 6B). This led to the maintenance of JNK activity at
levels that were even higher than the maximal activity seen in cells
treated with staurosporine alone (Fig. 6B).
These results demonstrate a correlative relationship between
JNK activation and JIP cleavage. In both TRAIL and staurosporine
treated HeLa cells, JNK activation reached its maximum at 2 h and
4 h respectively, immediately before the first detectable cleavage
of JIP1 by caspase-3 (4 h, Figs. 1, 2 and 6). The subsequent decrease
in JNK activity closely matched the kinetics of JIP1 cleavage andboth JIP1 cleavage and the decline in JNK activity were blocked by
pre-treatment with the caspase-3 inhibitor DEVD.fmk.
Cleavage of the JIP1 protein by caspase-3 causes disassembly
of the JNK/JIP1 complex
The JIP proteins have been proposed to facilitate the activation of
the JNK pathway by forming signalling complexes containing the
upstream kinases required for JNK activation. The decrease in JNK
activity observed at the onset of JIP1 cleavage by caspase-3
suggests that JIP1 is required for full activation of the JNK pathway
in response to TRAIL and staurosporine. To test if cleavage of JIP1
during apoptosis results in disassembly of the JIP1/JNK complex
we examined the co-immunoprecipitation of endogenous JIP1
with JNK in HeLa cells exposed to TRAIL in the presence or absence
of DEVD.fmk. Western blotting of control cell extracts shows that
both JIP1 and JNK are readily detected (Fig. 7A, top panel). As
expected, the addition of TRAIL resulted in the time-dependent
cleavage of JIP1 to a 100 kDa fragment, detectable in the cell
Fig. 6 – Effect of caspase-3 inhibition on JNK activation by TRAIL
and staurosporine in HeLa cells. HeLa cells were treated with
(closed symbols;●,▲) or without (open symbols;○,△) 1 μg/ml
TRAIL (A) or 1 μM staurosporine (B) in the presence (triangles;
△,▲) or absence (circles;○,●) of 40 μMDEVD.fmk. At the time
points indicated, cell lysates were prepared from adherent
and non-adherent cells, and JNK activity measured by
immune-complex kinase assay as described in Experimental
Procedures. The results shown represent the mean±SEM for
four independent experiments. Data points marked by
asterisks (*) indicate statistically significant differences at
p<0.05 in a two-tailed t-test.
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Neither TRAIL nor DEVD.fmk incubation had any effect on the level
of JNK detected in the cell extract during the time-course of the
experiment (Fig. 7A, top right panel). In control cells, no JIP1 was
detected in JNK immunoprecipitates (Fig. 7A, middle panel), with
JIP1 remaining in the supernatant (Fig. 7A, lower panel), thus
indicating no interaction between JNK and JIP1 in un-stimulated
cells. After stimulation with TRAIL for 2 h, JIP1 and JNK efficiently
co-precipitated, leaving little JIP1 remaining in the supernatant. At
this time point no cleavage of JIP1 was observed (Figs. 1A and 7A).
However, after 8 h of TRAIL treatment, by which time significantJIP1 cleavage was observed, the co-precipitation of JIP1 and JNK
was markedly decreased compared to that seen at 2 h, with
significant immunoreactivity remaining in the supernatant
(Fig. 7). In addition, the JIP1 that did co-precipitate with JNK at
this time point was the intact 120 kDa form of JIP1, and not the
cleaved 100 kDa form which was instead left behind in the
supernatant. In the presence of the caspase-3 inhibitor, DEVD.fmk,
the cleavage of JIP1 in response to TRAIL was blocked and JIP1 and
JNK co-precipitation was restored (Fig. 7). Taken together these
observations show that the interaction of JNK and JIP1 is
dependent on the presence of the intact 120 kDa form of JIP1
and that caspase-3-mediated JIP1 cleavage results in disassembly
of the JIP1/JNK complex.Discussion
We have previously shown enhanced JNK activation in response to
caspase inhibition during chemically-induced apoptosis [12]. An
inspection of the JIP1 protein sequence shows several potential
caspase cleavage sites [3]. This led us to believe that JNK activity in
apoptotic cells may be modulated by caspases due to proteolytic
cleavage of the JNK pathway scaffold protein JIP1. We investigated
this possibility in HeLa cells treated with TRAIL or staurosporine,
where we showed JIP1 to be cleaved to a 100 kDa fragment during
apoptosis by either stimulus. JIP1 cleavage correlated with the
progression of apoptosis, cleavage of the caspase-3 substrate, PARP
and activation of caspases. Its appearance was blocked by the
general caspase inhibitor zVAD.fmk and more specifically by the
caspase-3 inhibitor DEVD.fmk.
These data clearly demonstrate that JIP1 is a target for caspases
during apoptosis, and that cleavage of JIP1 in vivo is likely to be
mediated by caspase-3. To confirm the specificity of caspase
cleavage, and to detect additional JIP1 fragments generated by
caspase cleavage, but not observed by western blotting, we tested
the ability of caspase-3 and caspase-8 to cleave in vitro translated
JIP1 protein. These experiments showed that JIP1 was preferen-
tially cleaved by caspase-3 and was a poor substrate for caspase-8.
Caspase-3 digestion resulted in the production of three JIP1
fragments of sizes consistent with cleavage at two sites (DLID
and DESD). Cleavage at these sites was confirmed in vitro by site
directed mutagenesis and we found no evidence for cleavage at
other sites.
The JNK pathway is activated during apoptosis in many cell
types and this may be facilitated by the JIP family scaffold proteins.
If JIP1 were cleaved by caspases during apoptosis we would expect
this to affect JNK activation. To determine if JIP1 cleavage during
apoptosis had a functional consequence we measured the JNK
activity in cells undergoing apoptosis in response to TRAIL or
staurosporine in the presence and absence of the caspase-3
inhibitor DEVD.fmk. These experiments showed, as expected,
activation of JNK by TRAIL and staurosporine. This activation was,
however, transient, occurring during the initiation phase of
apoptosis, with JNK activity declining after approximately 2–4 h
and returning almost to basal levels at 8 h. The decline in JNK
activity in both TRAIL and staurosporine treated cells correlated
well with the cleavage of JIP1 by caspases. Furthermore, the
inactivation of JNK later in the time-course was blocked in the
presence of DEVD.fmk, leading to a sustained JNK activation in
Fig. 7 – Co-immunoprecipitation of JIP1 with JNK during apoptosis in HeLa cells. (A) HeLa cells were treatedwith or without 1 μg/ml
TRAIL in the presence or absence of 40 μM DEVD.fmk. At the time points indicated, cell lysates were prepared from adherent and
non-adherent cells. Extracts were either immunoprecipitated with anti-JNK antibody and extract, immunoprecipitate and
supernatant western blotted for JIP1, (left panel) or the extract alone blotted for JNK (right panel). (B) Western blots showing JNK
and JIP1 co-immunoprecipitation were quantified by densitometry and the data expressed as percentage retention of JIP1 in the
supernatant.
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caspase-mediated cleavage of JIP1 may contribute to a decrease in
JNK activity during the execution phase of apoptosis.
JIP scaffold proteins are believed to potentiate JNK activation by
forming multi-protein signalling complexes containing JNK and its
upstream activators [32,33,39,40]. However, the level of JIP
expression seems to be critically important in determining the
stoichiometry of such signalling complexes and either increased or
decreased expression of JIPs can inhibit JNK signalling [45,46].
Indeed, our attempts to test the effect of caspase-resistant JIP1
mutants on JNK activation and apoptosis in HeLa cells were
thwarted since exogenous expression of either wild-type or
caspase-resistant JIP1 was sufficient to inhibit JNK signalling and
block apoptosis (data not shown).
There are also good experimental correlations between JIP
levels and JNK activity in many cell types [31,40,47–52].
Disassembly of JIP/JNK signalling complexes due to caspase
cleavage of JIP1 could therefore contribute to the JNK inactivation
we observe during the execution phase of apoptosis. We tested
this by co-immunoprecipitation of endogenous JIP1 and JNK incells undergoing apoptosis. The interaction of JNK with JIP1 was
not observed in unstimulated cells, but was readily observed at
early time points during apoptosis, before JIP1 cleavage was
detected. At later time points, when there was significant JIP1
cleavage, JNK did not to co-precipitate with the cleaved 100 kDa
fragment of JIP1, which was left behind in the supernatant.
However, the intact JIP1 remaining at this time point was still able
to bind JNK. Co-immunoprecipitation was restored in the presence
of the caspase-3 inhibitor DEVD.fmk. This clearly shows that
cleavage of JIP1 by caspases results in disassembly of the JIP1/JNK
signalling complex even though the JNK binding domain, which is
C-terminal to the caspase cleavage site at DLID, is still intact.
Cleavage at the DESD site will separate the JNK binding domain
from the binding site for the MLK family of kinases, situated
towards the C-terminus of JIP1 in the PTB domain, and potentially
that for MKK7, thus uncoupling JNK from its upstream activators
[39,56]. Binding sites for othermolecules thatmay also be involved
in JNK regulation or affect its cellular location, such as kinesin,
MKP-7 and POSH may also be lost [44,57,58]. Consistent with the
observations of others [59], we find that JNK is not a direct target of
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points is therefore not a consequence of JNK proteolysis.
The fact that we do not see cleavage of all of the cellular JIP1 to
the 100 kDa fragment during apoptosis suggests that there may be
separate, caspase-sensitive and insensitive pools of JIP1. Consider-
ing the dynamic nature of JIP scaffold complexes that is now
emerging, where the activation state of the pathway may
determine which kinases are bound [see Fig. 7 and [60]], and the
abundance of proposed binding partners, including MKK7, MLK3
and JNK, it is possible that the accessibility of JIP1 to caspases may
be determined by the composition and activity of components of
the complex with some binding partners protecting JIP1 from
caspases. This may explain why we are able to detect additional
JIP1 cleavage products by digestion of JIP1 with caspases in vitro,
which are not apparent in vivo.
The cleavage of JNK pathway scaffold proteins by caspases is
not restricted to JIP1. JIP3, also known as JSAP1, is cleaved by
caspase-3 during apoptosis in NGF-deprived PC12 cells [33].
Inspection of the amino acid sequences of JIP2 and the more
recently identified JIP4/JLP scaffold also reveal potential caspase
cleavage sites. However, neither JIP2 nor JIP4 have yet been
confirmed as caspase substrates experimentally and further work
will be required to clarify this issue. Other MAPK scaffold proteins
also appear to be targets for caspases. The ERK pathway scaffold,
KSR1 is cleaved at a single site by caspase-3 during apoptosis [61],
resulting in a loss of scaffold activity by separation of the MEK and
ERK binding sites. This leads to down-regulation of ERK-mediated
survival signalling and thus promotion of apoptosis [61]. These
observations suggest that caspase-mediated cleavage of scaffold
proteins is likely to be a general mechanism for the modulation of
MAPK signalling during apoptosis.
Caspase-mediated cleavage of some signalling proteins, includ-
ing MEKK1 [62,63], Ras GAP [64] and PKCδ [65], can directly
promote apoptosis due to the production of pro-apoptotic
proteolytic fragments. More commonly, caspases may promote
apoptosis by inactivating proteins involved in signalling for cell
survival. The cleavage of KSR1, mentioned above, is a good
example. Others include the adapter proteins RIP and TRAF1
which when cleaved produce fragments which inhibit NF-kB
activation, promoting apoptosis [66–69]. Similarly, caspase-
mediated cleavage of Raf [59], Akt/PKB [70] and FAK [71,72] also
promote apoptosis by inactivating cell survival pathways.
Since JNK activation during apoptosis is generally thought to
contribute to cell death, where it appears to be required for stress-
induced activation of caspases, cleavage of a JNK scaffold protein
by caspases at first appears puzzling. However, the situation is
likely to be more complex. There are numerous reports that JNK
signalling in some instances may provide survival signals to
counteract cell death [23–30], perhaps acting via JunD/NF-kB-
mediated expression of the inhibitor of apoptosis cIAP-2 [26]. The
role of JNK in regulating apoptosis is also likely to depend on the
cell type, as well as the context and timing of JNK activation. In the
initiation phase of apoptosis, the extent of JNK activation, and
hence sensitivity of cells to apoptotic stimuli, may be dependent
on JIP levels. JNK activation appears to be required to enter the
execution phase, probably via activation of the mitochondrial
pathway. However once caspases have been activated and the cell
is committed to apoptosis, JNK activity may no longer be required.
Our data suggest that caspase-mediated cleavage of JIP1 may
contribute to the attenuation of JNK activity at later time points.This might prevent JNK exerting unwanted protective/survival
effects late during apoptosis, thus committing the cell to death.Conclusion
In summary, our data show JIP1 to be a target for caspase-3
mediated cleavage in response to both chemical and receptor-
mediated apoptotic stimuli. Caspase-3 cleaves JIP1 at two sites
leading to the disassembly of the JNK/JIP signalling complex
thought to be required for JNK activation. Caspase-3-mediated
cleavage of JIP1 may play a role in attenuating JNK activity late
during the execution phase of apoptosis, when its activity may no
longer be required. Cleavage of both ERK and JNK scaffold proteins
by caspases suggests a general mechanism for the regulation
MAPK signalling during apoptotic cell death.Acknowledgments
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